Results 231 to 240 of about 10,004,929 (375)

Small modifier, big decision: switching to SUMO mode adds weight to cancer stemness in mammary tumors

Molecular Oncology, EarlyView.
Inhibition of protein SUMOylation has been shown to block tumorigenesis; however, the specific mechanisms by which SUMOylation controls the tumor‐initiating capacities remain elusive. Li et al. describe the role of Etv1 SUMOylation in cancer stem cells using mouse models of mammary gland tumorigenesis.
Veronika Yevdokimova, Yannick D. Benoit
wiley   +1 more source

Performance of 18F-FDG PET/MRI and its parameters in staging and neoadjuvant therapy response evaluation in bladder cancer

iScience
Summary: 18F-FDG PET/MRI shows potential efficacy in the diagnosis of bladder cancer (BLCA). However, the performance of 18F-FDG PET/MRI in staging and neoadjuvant therapy (NAT) response evaluation for BLCA patients remains elusive. Here, we conduct this
Tianhang Li, Qinqin You, Shiwei Zhang, Rushuai Li, Shangxun Xie, Danyan Li, Shuyue Ai, Rong Yang, Hongqian Guo   +8 more
doaj  

Two decades of advances in clinical oncology - lessons learned and future directions. [PDF]

Nat Rev Clin Oncol
Banerjee S, Booth CM, Bruera E, Büchler MW, Drilon A, Fry TJ, Ghobrial IM, Gianni L, Jain RK, Kroemer G, Llovet JM, Long GV, Pantel K, Pritchard-Jones K, Scher HI, Tabernero J, Weichselbaum RR, Weller M, Wu YL.   +18 more
europepmc   +1 more source

UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology. [PDF]

Oncotarget, 2023
Price MJ, Nguyen AD, Byemerwa JK, Flowers J, Baëta CD, Goodwin CR.   +5 more
europepmc   +1 more source

Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: Long-term follow-up results. Japan Clinical Oncology Group Protocol 8902

, 2000
Kaoru Kubota, Tomohide Tamura, M. Fukuoka, Kiyoyuki Furuse, H Ikegami, Y Ariyoshi, Yuichi Kurita, Nagahiro Saijo   +7 more
openalex   +1 more source

Targeting carbonic anhydrase IX/XII prevents the anti‐ferroptotic effect of stromal lactic acid in prostate carcinoma

Molecular Oncology, EarlyView.
In prostate carcinoma, lactic acid, secreted by highly glycolytic cancer‐associated fibroblasts, is imported into tumor cells through the MCT1 transporter and prevents RSL3 and erastin‐induced ferroptosis (A). Targeting of carbonic anhydrase IX/XII, the main extracellular pH regulators, in tumor and stromal cells reduces microenvironmental acidosis and
Elisa Pardella, Giuseppina Comito, Luigi Ippolito, Erica Pranzini, Marta Iozzo, Giulia Gangarossa, Francesca Virgilio, Silvia Bua, Alessio Nocentini, Giada Sandrini, Nicla Lorito, Marina Bacci, Gabriella Nesi, Pietro Spatafora, Sergio Serni, Claudiu T. Supuran, Andrea Morandi, Paola Chiarugi, Elisa Giannoni   +18 more
wiley   +1 more source

Personalized medicine: Clinical oncology on molecular view of treatment. [PDF]

World J Clin Oncol
Da Silva RCDS, Simon NA, Dos Santos AA, Olegário GM, Da Silva JF, Sousa NO, Corbacho MAT, de Melo FF.   +7 more
europepmc   +1 more source

Machine learning for identifying liver and pancreas cancers through comprehensive serum glycopeptide spectra analysis: a case‐control study

Molecular Oncology, EarlyView.
This study presents a novel AI‐based diagnostic approach—comprehensive serum glycopeptide spectra analysis (CSGSA)—that integrates tumor markers and enriched glycopeptides from serum. Using a neural network model, this method accurately distinguishes liver and pancreatic cancers from healthy individuals.
Motoyuki Kohjima, Yuko Takami, Ken Kawabe, Kazuhiro Tanabe, Chihiro Hayashi, Mikio Mikami, Tetsuya Kusumoto   +6 more
wiley   +1 more source

Brain Drain in Cancer Care: The Shrinking Clinical Oncology Workforce in Nigeria. [PDF]

JCO Glob Oncol, 2023
Chidebe RCW, Orjiakor TC, Lasebikan N, Joseph A, Toland S, Simons A.   +5 more
europepmc   +1 more source

Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation

Molecular Oncology, EarlyView.
Cyclin D1 overexpression altered the cell adhesion pathway, while cyclin D2 upregulation had less impact on pathway enrichment analysis. Multiple myeloma (MM) patients with cyclin D1 overexpression showed reduced CD56 expression and increased circulating tumor cells (CTC) levels, suggesting that cyclin D1 may contribute to MM cell dissemination ...
Ignacio J. Cardona‐Benavides, Sara Cristobal‐Vargas, Cristina De Ramón, Elizabeta A. Rojas, Irena Misiewicz‐Krzeminska, Isabel Isidro, José Juan Pérez, Bruno Paiva, Noemi Puig, Miguel Alcoceba, María‐Victoria Mateos, Luis A. Corchete, Myriam Cuadrado, Norma C. Gutiérrez   +13 more
wiley   +1 more source